臨床バイオ銘柄のインサイダー情報

報告日 取得日 ティッカー インサイダー 役職 / 区分 取得株数 平均取得額 取得総額 保有形態
4/3 4/2 ANVS Hoffman Michael B Director 713,800株 $2.10 $1,498,980 Indirect / Direct(保有株数:3,511,896)
04/02 04/02 LPCN Patel Mahesh V. Chief Executive Officer 25,000株 $2.02 $50,500 Direct(保有株数:135,679)
03/31 04/02 ZBIO Lu Hongbo Director 3,768株 $18.63 $70,198 Indirect(保有株数:426,736)
03/31 04/01 ZBIO Fairmount Funds Management LLC
Fairmount Healthcare Fund II L.P.
Kiselak Tomas
Harwin Peter Evan
Director 150,000株 $20.00 $3,000,000 Indirect(保有株数:2,359,025)
03/30 04/01 PVLA JENKINS GEORGE M Director 445株 $112.30 $49,974 Indirect / Direct(保有株数:201,132)
03/31 03/31 ZBIO Lu Hongbo Director 75,000株 $20.00 $1,500,000 Indirect(保有株数:422,968)
03/31 03/30 ZBIO MOULDER LEON O JR Chief Executive Officer 54,000株 $18.91 $1,021,140 Indirect / Direct(保有株数:2,186,122)
03/31 03/30 RZLT Evans Daron CFO 10,000株 $2.85 $28,500 Indirect / Direct(保有株数:511,462)
03/31 03/27 MLYS RA CAPITAL MANAGEMENT L.P.
RA Capital Healthcare Fund LP
RA Capital Nexus Fund III L.P.
Kolchinsky Peter
Shah Rajeev M.
Director 369,000株 $23.75 $8,762,797 Indirect(保有株数:7,692,750)
03/31 03/27 IMNM SIEGALL CLAY B President and CEO 25,450株 $19.67 $500,602 Direct(保有株数:690,704)
2026-03-27 2026-03-30 LENZ George Jeffrey P. Director 5,592株 $8.9217 $49,890 Direct(保有株数:5,592)
2026-03-27 2026-03-30 LENZ Schimmelpennink Evert B. President, CEO and Secretary 28,089株 $8.9505 $251,411 Direct(保有株数:77,289)
2026-03-27 2026-03-30 LENZ Chevallard Daniel R. Chief Financial Officer 7,500株 $8.57 $64,275 Direct(保有株数:12,886)
03/23 03/25 SRZN TCG Crossover GP II LLC
TCG Crossover Fund II L.P.
TCG Crossover GP III LLC
TCG Crossover Fund III L.P.
10% Owner 121,881株 $24.72 $3,012,768 Indirect(保有株数:736,547)
03/23 03/19 IBIO Duran Felipe Chief Financial Officer 24,835株 $2.0186 $50,132 Direct(保有株数:35,974)
03/23 03/19 IBIO Brenner Martin See Remarks 12,336株 $2.02 $24,919 Direct(保有株数:30,652)
03/13 03/16 MBX Hawryluk P. Kent President & CEO 18,500株 $28.41 $525,663 Direct / Indirect(保有株数:1,215,051)
03/12 03/16 SRZN TCG Crossover GP II LLC
TCG Crossover Fund II L.P.
TCG Crossover GP III LLC
TCG Crossover Fund III L.P.
10% Owner 48,997株 $24.91 $1,220,362 Indirect(保有株数:675,610)
03/10 03/12 KRRO Yang Rick 10% Owner 207,100株 $11.11 $2,300,881 Indirect(保有株数:1,540,838)
03/10 03/12 KRRO SANDELL SCOTT D 10% Owner 207,100株 $11.11 $2,300,881 Indirect(保有株数:1,540,838)
03/10 03/12 KRRO New Enterprise Associates 17 L.P.
NEA Partners 17 L.P.
NEA 17 GP LLC
10% Owner 207,100株 $11.11 $2,300,881 Direct(保有株数:1,540,838)
03/10 03/12 KRRO Chang Carmen 10% Owner 207,100株 $11.11 $2,300,881 Indirect(保有株数:1,540,838)
03/10 03/12 KRRO BASKETT FOREST 10% Owner 207,100株 $11.11 $2,300,881 Indirect(保有株数:1,540,838)
03/10 03/12 KRRO Mathers Edward T 10% Owner 207,100株 $11.11 $2,300,881 Indirect(保有株数:1,540,838)
03/10 03/12 KRRO Makhzoumi Mohamad 10% Owner 207,100株 $11.11 $2,300,881 Indirect(保有株数:1,540,838)
03/10 03/12 KRRO Walker Paul Edward 10% Owner 207,100株 $11.11 $2,300,881 Indirect(保有株数:1,540,838)
03/10 03/12 KRRO Florence Anthony A. Jr. 10% Owner 207,100株 $11.11 $2,300,881 Indirect(保有株数:1,540,838)
03/09 03/06 ARVN Morrison Briggs Director 20,000株 $13.40 $268,070 Direct(保有株数:96,021)
03/09 03/06 ALT WEAVER GREGORY L Chief Financial Officer 5,000株 $3.54 $17,700 Direct(保有株数:28,078)
03/09 03/06 ALT Durso Jerome Benedict President and CEO 20,000株 $3.5395 $70,790 Direct(保有株数:32,500)
03/03 03/02 EDSA Nijhawan Pardeep Chief Executive Officer / 10% Owner 3,000株 $2.0932 $6,280 Indirect・Direct(保有株数:1,118,241)
03/02 02/27 ABCL Thermopylae Holdings Ltd. 10% Owner 38,000株 $3.44 $130,720 Direct(保有株数:56,134,097)
03/02 02/27 LRMR Hamilton Thomas Edward Director 100,000株 $5 $500,000 Indirect / Direct(保有株数:824,231)
03/02 02/27 LRMR THOMAS FRANK E Director 5,000株 $5 $25,000 Direct(保有株数:7,000)
03/02 02/27 LRMR SHERMAN JEFFREY W Director 5,000株 $5 $25,000 Direct(保有株数:5,000)
03/02 02/26 EDSA Nijhawan Pardeep Chief Executive Officer / 10% Owner 50,571株 $1.9611 $99,176 Indirect・Direct(保有株数:1,115,241)
02/27 02/27 ABCL Booth Andrew Chief Financial Officer 42,600株 $3.42 $145,692 Indirect / Direct(保有株数:326,559)
02/26 02/27 ABCL Thermopylae Holdings Ltd. 10% Owner 177,457株 $3.27 $580,284 Direct(保有株数:56,096,097)
02/25 02/27 LXRX Debbane Raymond Director 2,000株 $1.49 $2,980 Indirect / Direct(保有株数:51,660,909)
02/23 02/25 LXRX Debbane Raymond Director(Purchase) 100,000株 $1.47 $147,000 Indirect / Direct(保有株数:51,658,909)
02/20 02/23 CVRX Jain Mudit K. Director 46,800株 $6.3588 $297,592 Indirect / Direct(保有株数:985,833)
02/19 02/23 LXRX Debbane Raymond Director 150,000株 $1.465 $219,755 Indirect / Direct(保有株数:51,558,909)
02/18 02/18 CVRX Jain Mudit K. Director 600株 $4.6417 $2,785 Indirect / Direct(保有株数:939,033)
2026/02/13 2026/02/18 LXRX Debbane Raymond Director 268,497株 $1.3143 $352,889 Indirect / Direct(保有株数:51,408,909)
12/18 02/17 KLRS AKKARAJU SRINIVAS Director / 10% Owner 479,847株 $10.42 $5,000,006 Indirect(保有株数:12,948,081)
02/03 02/05 PMN Yu Fan / Alex Slanix Paul
(ABG Management Ltd.
Ally Bridge MedAlpha Master Fund L.P.
Ally Bridge Group (NY) LLC)
10% Owner 700,741株 $12.13 $8,499,988 Indirect(保有株数:1,643,831)
02/02 02/04 ALXO Goodman Corey S Director / 10% Owner 3,184,713株 $1.57 $4,999,999 Indirect(保有株数:13,052,008)
02/02 02/03 ZBIO Moulder Leon O Jr Chief Executive Officer 57,000株 $17.96 $1,023,720 Direct / Indirect(保有株数:2,132,122)
01/21 01/21 CABA Chang David J. Chief Medical Officer 8,800株 $2.26 $19,888 Direct(保有株数:8,800)
01/30 02/02 ELUT Rakin Kevin
(HighCape Partners GP II LLC /
HighCape Partners GP II L.P. /
HighCape Partners QP II L.P.)
Director / 10% Owner 70,000株 $1.06 $74,200 Direct / Indirect(保有株数:5,225,098)
01/30 02/02 ELUT Neels Guido J Director 20,000株 $1.04 $20,800 Direct(保有株数:118,750)
01/28 01/29 ELUT Neels Guido J Director 30,000株 $1.06 $31,800 Direct(保有株数:98,750)
01/21 01/21 CABA Binder Gwendolyn President, Science & Tech. 11,312株 $2.1891 $24,763 Direct(保有株数:31,312)
01/21 01/21 CABA Tomasello Shawn Director 22,725株 $2.2144 $50,322 Indirect(保有株数:22,725)
01/21 01/21 CABA Gavel Steve Chief Commercial Officer 22,170株 $2.265 $50,215 Direct(保有株数:22,170)
01/21 01/21 CABA Bollard Catherine Director 4,405株 $2.2661 $9,982 Direct(保有株数:5,405)
01/21 01/21 CABA Nichtberger Steven President & CEO 45,000株 $2.2395 $100,778 Indirect / Direct(保有株数:1,394,483)
01/21 01/21 CABA Simon Mark Director 11,061株 $2.2838 $25,261 Indirect / Direct(保有株数:154,205)
01/21 01/21 CABA Gerard Michael General Counsel 6,600株 $2.2696 $14,979 Direct(保有株数:6,600)
01/16 01/21 PALI Williams Donald Allen Director 5,000株 $1.6712 $8,356 Indirect / Direct(保有株数:13,728)
01/16 01/20 ONCY Seizinger Bernd R. Director 100,000株 $1.0377 $103,770 Direct(保有株数:466,991)
01/14 01/16 ACRV Blume-Jensen Peter / Masson Kristina President and CEO 49,000株 $1.676 $82,124 Direct / Indirect(保有株数:2,410,477)
01/14 01/16 ACRV Levy Adam D. Chief Financial Officer 8,832株 $1.6983 $14,999 Direct(保有株数:20,983)
01/13 01/15 ACRV Devroe Eric Chief Operating Officer 10,000株 $1.7218 $17,218 Direct(保有株数:75,308)
01/12 01/14 IMRX Feinberg Peter Director 20,000株 $4.3452 $86,904 Indirect / Direct(保有株数:1,161,064)
01/09 01/13 PALI Williams Donald Allen Director 5,000株 $1.88 $9,400 Indirect / Direct(保有株数:8,728)
01/09 01/13 ALMS AKKARAJU SRINIVAS Director 588,235株 $17.00 $9,999,995 Indirect(保有株数:6,345,219)
01/08 01/12 ALMS Foresite Labs LLC
Foresite Labs Affiliates 2021 LLC
10% Owner 411,764株 $17.00 $6,999,988 Indirect(保有株数:10,487,268)
01/08 01/12 ALMS Foresite Capital Management VI LLC
Foresite Capital Management V LLC
Foresite Capital Fund V L.P.
Foresite Capital Opportunity Management V LLC
Foresite Capital Opportunity Fund V L.P.
Foresite Capital Fund VI LP
Labs Co-Invest V LLC
Foresite Labs Management I LLC
Foresite Labs Fund I L.P.
10% Owner 411,764株 $17.00 $6,999,988 Indirect(保有株数:10,487,268)
01/08 01/12 ALMS Tananbaum James B. Director / 10% Owner 411,764株 $17.00 $6,999,988 Indirect(保有株数:10,487,268)
01/08 01/09 ALT Pisano Wayne Director 5,000株 $4.082 $20,410 Direct(保有株数:13,498)
01/07 01/09 ZBIO Moulder Leon O Jr Chief Executive Officer 100,000株 $16.39 $1,639,000 Direct(保有株数:2,075,122)
01/05 01/07 PMCB Silverman Joshua CEO and President 100,000株 $0.80476 $80,476 Direct / Indirect(保有株数:466,250)
01/05 01/07 PMCB Schechter Jonathan Director 60,000株 $0.80387 $48,232 Direct(保有株数:192,500)
01/05 01/07 CLYM RA Capital Management, L.P.
(RA Capital Healthcare Fund LP 他)
Kolchinsky Peter / Shah Rajeev M.
Director / 10% Owner 7,111株 $3.50 $24,889 Indirect(保有株数:11,300,939)
01/05 01/05 ALT Sohn Catherine A. Director 500株 $4.2351 $2,118 Direct(保有株数:1,500)
01/02 01/06 RCKT Bjork Elisabeth Director 10,000株 $3.44 $34,400 Direct(保有株数:50,000)
01/02 12/30 FBRX Riley Antony A Chief Financial Officer 9,680株 $26.33 $254,833 Direct(保有株数:43,241)
12/23 12/29 BNTC SUVRETTA CAPITAL MANAGEMENT LLC Director / 10% Owner 144,223株 $13.20 $1,903,133 Indirect(保有株数:1,848,156)
12/23 12/23 ALT GILL JOHN Director 12,500株 $4.10 $51,250 Direct(保有株数:12,500)
12/22 12/29 IPSC Cowan Chad Chief Scientific Officer 58,060株 $0.8483 $49,252 Indirect / Direct(保有株数:1,055,784)
12/22 12/22 ALT Durso Jerome Benedict Director 12,500株 $4.1255 $51,569 Direct(保有株数:12,500)
12/19 12/23 TCRX Lynx1 Capital Management LP / Nichols Weston 10% Owner 161,801株 $0.89941 $145,526 Indirect(保有株数:8,019,148)
12/19 12/22 IMNM SIEGALL CLAY B President and CEO 7,278株 $20.48 $149,053 Direct(保有株数:660,525)
12/19 12/22 IMNM Tsai Philip Chief Technical Officer 10,000株 $20.49 $204,900 Direct(保有株数:43,300)
12/18 12/22 BNTC SUVRETTA CAPITAL MANAGEMENT LLC / Cowen Aaron
Averill Master Fund Ltd.
Averill Madison Master Fund Ltd.
Director / 10% Owner 46,141株 $11.68 $538,972 Indirect(保有株数:1,826,653)
12/18 12/18 IMNM SIEGALL CLAY B President and CEO 46,511株 $21.50 $999,987 Direct(保有株数:853,247)
12/18 12/22 KYTX SEIDENBERG BETH C Director 133,333株 $7.50 $999,998 Direct / Indirect(保有株数:4,673,891)
12/18 12/22 KYTX Westlake BioPartners Opportunity Fund I L.P. 他 10% Owner 133,333株 $7.50 $999,998 Indirect(保有株数:4,657,257)
12/15 12/15 RZLT Evans Daron CFO 45,000株 $1.7684 $79,578 Indirect / Direct(保有株数:505,900)
12/15 12/15 RZLT Elam Nevan C CEO 32,000株 $1.59 $50,880 Direct(保有株数:641,119)
12/15 12/15 RZLT Karnawat Sunil Ratilal Chief Commercial Officer 12,100株 $1.6197 $19,599 Indirect / Direct(保有株数:81,440)
12/12 12/16 IPSC Pfeiffenberger Brent President and CEO 52,000株 $0.5837 $30,352 Direct(保有株数:3,322,990)
12/12 12/12 IMVT Roivant Sciences Ltd. Director / 10% Owner 16,666,666株 $21.00 $349,999,986 Direct(保有株数:113,317,007)
12/11 12/15 CLYM RA Capital Management L.P. Director / 10% Owner 314,561株 $2.3993 $754,737 Indirect(保有株数:31,733,828)
12/11 12/15 WVE GSK plc 10% Owner 1,470,000株 $19.00 $27,930,000 Indirect(保有株数:18,245,691)
12/08 12/10 TENX Rich Stuart Chief Medical Officer 5,000株 $10.16 $50,792 Indirect / Direct(保有株数:1,137,993)
12/04 12/08 SRZN Kutzkey Tim Director / 10% Owner 36,150株 $19.22 $694,850 Indirect(保有株数:1,326,717)
12/04 12/08 SRZN COLUMN GROUP III(関連LP/GP) 10% Owner 36,150株 $19.22 $694,850 Indirect(保有株数:1,326,717)
12/02 12/05 TENX Rich Stuart Chief Medical Officer 5,000株 $9.1244 $45,622 Indirect / Direct(保有株数:1,132,993)
11/28 12/01 KTTA STEINMAN LAWRENCE Director 133,333株 $0.75 $100,000 Direct(保有株数:199,691)
11/28 12/01 KTTA Marques Tiago Chief Executive Officer 33,333株 $0.75 $25,000 Direct(保有株数:73,334)
11/28 12/01 KTTA Dumesnil Simon Director 33,333株 $0.75 $25,000 Direct(保有株数:35,833)
11/25 11/25 VRCA Rosenberg Noah L. CMO 2,357株 $4.2425 $10,000 Direct(保有株数:2,946)
11/25 11/25 VRCA Kirby John J. Interim CFO 3,536株 $4.2425 $15,001 Direct(保有株数:9,846)
11/25 11/25 VRCA Zawitz David Chief Operating Officer 10,000株 $4.2425 $42,425 Direct(保有株数:23,500)
11/25 11/25 VRCA Rieger Jayson CEO and President 94,311株 $4.2425 $400,114 Indirect / Direct(保有株数:206,875)
11/25 11/25 VRCA Manning Paul B Director / 10% Owner 4,126,142株 $4.2425 $17,505,157 Indirect / Direct(保有株数:8,963,753)
11/25 11/21 DCTH Sylvester John Richard Director 4,386株 $8.89 $38,992 Direct(保有株数:14,936)
11/25 11/19 TRDA 新規(13G) TCG Crossover GP I, LLC 1,917,344株(+新規) 5.000%
11/24 11/20 TRDA BAKER BROS. ADVISORS LP
Baker Bros. Advisors (GP) LLC
BAKER FELIX / BAKER JULIAN
10% Owner 28,867株 $9.0708 $261,846 Indirect(保有株数:4,691,392)
11/19 11/20 IVVD Kevin F. McLaughlin Director 50,000株 $2.50 $125,000 Direct
11/19 11/17 TENX Thomas McGauley Interim CFO 8,000株 $7.2705 $58,164 Indirect / Direct(7,000)
11/19 11/17 TENX June Sherie Almenoff Director 1,993株 $7.4986 $14,945 Direct(182,001)
11/19 11/17 CRVO Matthew Winton Chief Commercial and Business 5,000株 $8.286 $41,430 Direct(15,000)
11/19 11/17 CRVO Sylvie Gregoire Director / 10% Owner 21,600株 $8.46 $182,736 Indirect / Direct(1,496,578)
11/19 11/17 CRVO William Robert Elder CFO, GC & Secretary 3,500株 $8.3571 $29,250 Direct(12,500)
11/19 11/17 CRVO John J. Alam CEO & President / 10% Owner 21,600株 $8.46 $182,736 Indirect / Direct(1,496,578)
11/17 11/13 SRZN COLUMN GROUP III GP LP
COLUMN GROUP III-A LP
COLUMN GROUP III LP
Column Group Opportunity III LP
Column Group Opportunity III GP LP
TCG Opportunity III GP LLC
10% Owner 315,457株 $12.65 $3,990,531 Indirect(1,307,545)
11/18 11/17 BHVN George C. Clark VP, Chief Accounting Officer 17,000株 $8.5159 $144,770 Indirect / Direct(85,595)
11/17 11/13 CRVO Sylvie Gregoire Director / 10% Owner 7,847株 $7.5317 $59,101 Indirect / Direct(1,474,978)
11/17 11/14 CRVO Matthew Winton Chief Commercial & Business 10,000株 $7.57 $75,700 Direct(10,000)
11/17 11/13 CRVO John J. Alam CEO & President / 10% Owner 7,847株 $7.5317 $59,101 Indirect / Direct(1,474,978)
11/17 11/13 BHVN Gregory Bailey Director 400,000株 $7.50 $3,000,000 Direct(2,020,071)
11/17 11/13 BHVN John W. Childs Director 3,333,333株 $7.50 $24,999,998 Indirect(9,876,729)
11/17 11/13 BHVN Vlad Coric Chief Executive Officer 666,666株 $7.50 $4,999,995 Indirect / Direct(2,647,259)
11/14 11/13 WVE RA Capital Management L.P.
RA Capital Healthcare Fund LP
Peter Kolchinsky
Rajeev M. Shah
Director / 10% Owner 1,000株 $6.6875 $6,688 Indirect(18,231,824)
11/13 11/12 CRVO Sylvie Gregoire Director / 10% Owner 5,553株 $7.35 $40,815 Direct(1,467,131)
11/13 11/12 CRVO William Robert Elder CFO, GC & Secretary 3,500株 $7.44 $26,040 Direct(9,000)
11/13 11/12 CRVO John J. Alam CEO & President / 10% Owner 5,553株 $7.35 $40,815 Direct(1,467,131)
11/13 11/11 DCTH MICHEL GERARD J Chief Executive Officer 11,500株 $8.526 $98,049 Direct(保有株数:330,834)
11/12 11/10 TRDA BAKER BROS. ADVISORS LP
Baker Bros. Advisors (GP) LLC
BAKER FELIX / BAKER JULIAN
10% Owner 178,044株 $7.5969 $1,352,587 Indirect(保有株数:4,664,924)
11/12 11/10 APVO Grady Grant III Director 13,513株 $1.49 $20,134 Direct(13,514)
11/12 11/07 EVMN RA Capital Management L.P. Director / 10% Owner 1,250,000株 $16 $20,000,000 Indirect(784,345)
11/12 11/07 EVMN LSP 7 Cooperative UA 10% Owner 1,562,500株 $16 $25,000,000 Direct(4,929,633)
11/12 11/07 EVMN Felice Isabel Verduyn-van Weegen Director / 10% Owner 1,562,500株 $16 $25,000,000 Indirect(4,929,633)
11/12 11/11 CERT William F. Feehery Chief Executive Officer 24,096株 $8.30 $200,000 Direct(2,360,769)
11/12 11/10 APVO Grady Grant III Director 13,513株 $1.49 $20,134 Direct(13,514)
11/10 11/07 BNTC SUVRETTA CAPITAL MANAGEMENT LLC / Averill Madison Master Fund Ltd. / Averill Master Fund Ltd. / Cowen Aaron Director / 10% Owner 1,481,481株 $13.5 $19,999,994 Indirect(保有株数:1,819,812)
11/10 11/07 LENZ James W. McCollum Director 10,500株 $22.79 $239,278 Indirect / Direct(631,099)
11/10 11/07 BNTC SUVRETTA CAPITAL MANAGEMENT LLC
Averill Madison Master Fund Ltd.
Averill Master Fund Ltd.
Cowen Aaron
Director / 10% Owner 1,481,481株 $13.5 $19,999,994 Indirect(保有株数:1,819,812)
11/07 11/07 LENZ Daniel R. Chevallard Chief Financial Officer 2,198株 $22.76 $50,017 Direct(5,386)
10/30 10/28 MPLT Novo Holdings A/S 10% Owner 952,941株 $17 $16,199,997 Direct(3,686,622)
10/29 10/28 MLPT Catalyst4 Inc. 10% Owner 5,441,176株 $17 $92,499,992 Indirect(19,697,464)
10/27 10/23 RANI Imran Mir A Director / 10% Owner 2,083,334株 $0.605 $1,260,417 Indirect / Direct(26,900,860)
10/23 10/21 NEUP Lynx1 Capital Management LP
Weston Nichols
10% Owner 639,110株 $5.137 $3,283,108 Indirect(875,328)
10/07 10/03 IMRX Peter Feinberg Director 7,500株 $6.67 $50,025 Indirect / Direct(1,141,064)
10/02 10/01 IMRX Mallory Morales Chief Accounting Officer 300株 $6.39 $1,917 Direct(27,533)
10/02 10/01 IMRX Leah R. Neufeld Chief People Officer 800株 $6.3792 $5,103 Direct(23,344)
10/02 10/01 IMRX Michael Bookman Chief Legal Officer / Secretary 1,020株 $6.8299 $6,966 Direct(4,870)
10/01 09/30 PEPG Oxford Science Enterprises plc Former 10% Owner 200,000株 $3.20 $640,000 Direct(4,955,388)
09/30 09/26 PEPG RA Capital Management L.P.
RA Capital Healthcare Fund LP
RA Capital Nexus Fund II L.P.
Peter Kolchinsky
Rajeev M. Shah
Director / 10% Owner 9,375,000株 $3.20 $30,000,000 Indirect(20,064,545)
09/09 09/08 KURA Troy Edward Wilson President & CEO 50,000株 $8.2029 $410,145 Indirect / Direct(680,162)
08/14 08/12 KURA Troy Edward Wilson President & CEO 50,000株 $6.064 $303,201 Indirect / Direct(630,162)
08/04 07/31 LRMR James E. Flynn
Deerfield Management Company L.P.
Deerfield Mgmt III L.P.
Deerfield Mgmt HIF L.P.
Deerfield Mgmt IV L.P.
Deerfield Mgmt L.P.
Deerfield Private Design Fund III L.P.
Deerfield Healthcare Innovations Fund L.P.
Deerfield Private Design Fund IV L.P.
Deerfield Partners L.P.
Director(Deputization) / 10% Owner 9,375,000株 $3.20 $30,000,000 Indirect(11,529,111)
07/01 06/27 SION TPG GP A LLC
James G. Coulter
Jon Winkelried
10% Owner 60,000株 $15.84 $950,400 Indirect(6,744,962)
06/30 06/27 TERN Andrew Gengos Chief Financial Officer 10,000株 $3.9283 $39,283 Direct(25,000)
06/26 06/25 RZLT Brian Kenneth Roberts Chief Medical Officer 2,500株 $4.3756 $10,939 Indirect / Direct(174,228)
06/25 06/25 TERN Amy L. Burroughs Chief Executive Officer 23,314株 $3.8702 $90,230 Direct(47,083)
06/24 06/24 RZLT Daron Evans CFO 5,000株 $4.05 $20,250 Indirect / Direct(360,900)
06/23 06/13 RZLT Young-Jin Kim Director 1,230,769株 $3.25 $3,999,999 Indirect / Direct(8,573,336)
06/23 06/13 RZLT Nerissa Kreher Director 3,076株 $3.25 $9,997 Direct(37,576)
06/23 06/20 SVRA Richard J. Hawkins Director 48,225株 $2.044 $98,572 Direct(115,466)
06/16 06/13 TERN Andrew Gengos Chief Financial Officer 15,000株 $3.8055 $57,083 Direct(15,000)
06/06 06/05 IOVA Daniel Gordon Kirby Chief Commercial Officer 30,000株 $1.84 $55,200 Direct(30,000)
06/02 05/29 SVRA Joseph S. McCracken Director 10,000株 $2.0825 $20,825 Direct(260,837)
05/27 05/23 IOVA Raj K. Puri Chief Regulatory Officer 5,600株 $1.7399 $9,743 Direct(206,852)
05/16 05/14 IOVA Frederick G. Vogt Interim CEO & General Counsel 25,000株 $1.69 $42,250 Direct(374,646)
05/12 05/07 PTN Robert K. Deveer Jr. Director 100,000株 $0.1018 $10,180 Direct(138,065)
03/18 03/14 GUTS Ajay Royan Director / 10% Owner 17,901株 $1.2837 $22,980 Indirect / Direct(6,430,102)
03/18 03/14 GUTS Kelly Ann Barnes Director 31,000株 $1.2971 $40,210 Direct(31,000)
03/17 03/13 GUTS Amy W. Schulman Director 8,550株 $1.1654 $9,964 Direct(8,550)
03/17 03/13 GUTS William Bradley Director 16,129株 $1.2622 $20,358 Direct(16,129)
03/17 03/13 GUTS Samuel Conaway Director 8,550株 $1.1654 $9,964 Direct(8,550)
02/12 02/10 SION TPG GP A LLC
James G. Coulter
Jon Winkelried
10% Owner 1,125,000株 $18 $20,250,000 Indirect(6,684,962)
02/10 02/10 SION RA Capital Management L.P.
RA Capital Healthcare Fund LP
RA Capital Nexus Fund L.P.
RA Capital Nexus Fund III L.P.
Peter Kolchinsky
Rajeev M. Shah
Director / 10% Owner 1,125,000株 $18 $20,250,000 Indirect(2,324,498)
02/10 02/10 SION OrbiMed Advisors LLC
OrbiMed Capital GP VIII LLC
Director 550,000株 $18 $9,900,000 Indirect(3,704,959)
02/10 02/10 SION Peter A. Thompson Director 550,000株 $18 $9,900,000 Indirect(3,704,959)
02/10 02/10 SION Bruce Booth Director 60,000株 $18 $1,080,000 Indirect(807,727)
02/10 02/10 SION Atlas Venture Fund XI L.P.
Atlas Venture Associates XI L.P.
Atlas Venture Associates XI LLC
Atlas Venture Opportunity Fund II L.P.
Atlas Venture Associates Opportunity II LP
Atlas Venture Associates Opportunity II LLC
10% Owner 60,000株 $18 $1,080,000 Indirect / Direct(3,694,020)

Clinical Bio(最新5件)

【SLDB】Solid Biosciences のカタリストとロードマップ

ハイライト 2025年12月16日:米HHSの推奨プロセスにおいて、Duchenne型筋ジストロフィー(DMD)が新生児スクリーニング推奨統一パネル(RUSP)に追加されるよう勧告(早期診断→治療介入の追い風)。 :co […]

【ABVX】Abivax のカタリストとロードマップ

Abivax (ABVX) のこれまでの臨床フェーズを見て気になったのが、2022年10月11日の初患者登録から2025年7月22日のトップライン発表まで、約2年9か月を要した点です。 なぜこのような時間を要したかという […]

【ACLX】Arcellx 臨床フェーズのロッドマップとカタリスト

臨床試験パイプライン & 提携状況 Phase 2 → 3 CART-ddBCMA(anitocabtagene autoleucel/BCMA CAR-T) 対象:再発/難治性多発性骨髄腫(RRMM) 治療: […]

【BBOT】BridgeBio Oncology Therapeutics 今後のカタリストとロードマップ

BridgeBio Oncology Therapeutics (BBOT) は KRAS経路を標的とした臨床段階の分子療法プログラムを3つ展開する臨床ステージのバイオ企業です。 2025年8月にSPACを通じて Bri […]

【CTMX】CytomX Therapeutics カタリストとロードマップ

バイオファンドの2025年第2四半期(Q2)の13F報告書を見ていて気になったのが、CTMX です。私も以前ロングしていたのですが、ものすごいハイボラで一度手放していました。 かなり多くのバイオファンドや、バイオにセンス […]

【TSHA】Taysha Gene Therapies 今後のカタリストとロードマップ

最新の Q2 2025 決算および企業発表に基づいて整理した、Taysha Gene Therapies(TSHA)の臨床試験ロードマップです。 TSHA-102(レット症候群向け遺伝子治療)のロードマップ ① REVE […]

【LRMR】Larimar Therapeutics 今後のカタリストとロードマップ

Larimar Therapeutics (ラリマー・セラピューティクス / LRMR) は、複雑な希少疾患の治療法開発に特化した臨床段階のバイオテクノロジー企業です。 Larimar の主要化合物である「nomlabo […]

【JANX】Janux Therapeutics 今後のカタリストとロードマップ

「JANX007」は何がスゴいのか!? JANX007 は「腫瘍内で “外れる二重マスク” を仕込んだPSMA×CD3のT細胞架橋薬(TRACTr)」で、高いPSA低下と良好な安全性(CRSは主にGrade 1–2、初回 […]

【GHRS】GH Research PLC 今後のカタリストとロードマップ

GH Research PLC (GHRS) は、精神疾患・神経疾患の治療を変革することを目的にした、臨床ステージのバイオ医薬品企業です。主に、5‑MeO‑DMT(メブフォテニン)を活用した治療候補(製剤技術)を複数開発 […]

【VSTM】Verastem のカタリストとロードマップ

Verastem Oncology(Nasdaq:VSTM)は、米国マサチューセッツ州ニーダム拠点の開発ステージのバイオ医薬品企業です。がん治療薬の研究開発および商業化に注力しています。 「がん患者が治療の選択肢を尽くさ […]